...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >CRITICAL REVIEW OF PHARMACOGENOMICS IN ANTIPARKINSONIAN DRUG THERAPY: IMPACT ON CLINICAL MANAGEMENT OF PARKINSON’S DISEASE
【24h】

CRITICAL REVIEW OF PHARMACOGENOMICS IN ANTIPARKINSONIAN DRUG THERAPY: IMPACT ON CLINICAL MANAGEMENT OF PARKINSON’S DISEASE

机译:帕金森病药物治疗中药物基因组学的重要综述:对帕金森病临床治疗的影响

获取原文
           

摘要

Parkinson’s disease is a progressive neurodegenerative disorder characterized by rest tremors, bradykinesia , rigidity , postural instability , gait dysfunction and several non motor symptoms . The marked difference in drug response and adverse effect profile among patients led to search of genetic markers and polymorphism associated with response to antiparkinsonian drugs which will enable us to predict an individuals response to drugs in terms of both efficacy and toxicity. Hence efforts to define the role of genetic polymorphism in optimizing pharmacotherapy of Parkinson’s disease have been undertaken and some promising genetic loci for the treatment have been determined. Therefore we aim to present a critical review of pharmacogenetic aspects of levodopa , dopamine agonists and COMT inhibitors and describe gene polymorphism of interest for future research.
机译:帕金森氏病是一种进行性神经退行性疾病,其特征为静息震颤,运动迟缓,僵硬,姿势不稳,步态功能障碍和几种非运动症状。患者之间药物反应和不良反应的显着差异导致寻找与抗帕金森病药物反应相关的遗传标记和多态性,这将使我们能够从功效和毒性方面预测个体对药物的反应。因此,已经做出努力来确定遗传多态性在优化帕金森氏病药物治疗中的作用,并确定了一些有希望的遗传基因位点用于治疗。因此,我们旨在对左旋多巴,多巴胺激动剂和COMT抑制剂的药理遗传学方面进行重要综述,并描述感兴趣的基因多态性,以备将来研究之用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号